Alto Neuroscience, Inc.
Alto Neuroscience, Inc. (ANRO): 6 pipeline candidates · ~29 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
29.4 months
D/E 0.14 · 0% dilution
Lead: Phase 2
6 candidates
N/A
N/A
A transparent, data-derived signal for Alto Neuroscience, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$742.9M
Cash
$264.3M
Quarterly Burn
$27.1M
Runway
29.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
107
Total value held
$493.7M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 4,019,786 | $90.4M |
| commodore capital lp | 2,723,196 | $61.2M |
| vanguard capital management llc | 2,414,050 | $54.3M |
| franklin resources inc | 1,101,874 | $24.8M |
| armistice capital, llc | 912,000 | $20.5M |
| millennium management llc | 821,982 | $18.5M |
| 72 investment holdings, llc | 667,778 | $15.0M |
| blackrock, inc. | 666,188 | $15.0M |
| susquehanna international group, llp | 637,598 | $14.3M |
| ikarian capital, llc | 515,000 | $11.6M |
Showing top 10 of 107 institutional holders of Alto Neuroscience, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Alto Neuroscience, Inc.'s pipeline?
Alto Neuroscience, Inc. (ANRO) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Alto Neuroscience, Inc.'s lead drug candidate?
Alto Neuroscience, Inc.'s most advanced tracked candidate is ALTO-100 (Phase 2) for Treatment-resistant Depression (TRD).
What is Alto Neuroscience, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Alto Neuroscience, Inc. has approximately 29.4 months of cash runway.
What is Alto Neuroscience, Inc.'s market capitalization?
Alto Neuroscience, Inc.'s market capitalization is approximately $742.9M.
Who is the CEO of Alto Neuroscience, Inc.?
Dr. Amit Etkin M.D., Ph.D. is the chief executive officer of Alto Neuroscience, Inc. (ANRO).
Get the full picture on Alto Neuroscience, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.